GNTXGENTEX CORPORATIONMid cap · $5.09B · FY ending 2025-12-31
$23.91-1.20% · 2026-07-13 · EOD
51/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality74
narrow moat · ROIC 17%Value79
P/E 13.7 · 38% of 12-mo rangeMomentum46
golden · price above 200-daySmart Money5
selling · 1 funds · 0P/9S insidersMixed trendGolden cross (fresh)Above 200-day
vs S&P 500-11.8%
6-mo excess Trailing performance1M -2.9%
3M +8.7%
6M -3.1%
YTD +0.9%
1Y +2.7%
P/E vs its last 12 months (our price history): 11.9 low → 16.7 high
Current price sits at the 38th percentile of that window — mid-range. We only compare against the price history we own (no paid multi-year multiples — nothing invented).
Narrow moat — ROIC 17%
Piotroski F6/9
fundamental strength Altman ZSafe
bankruptcy zone ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 17%. Annual figures from SEC XBRL.
Dividend & capital return
Payout ratio27.8%
comfortable Shareholder yield8.3%
dividends + buybacks Annual figures from SEC cash-flow statements. Shareholder yield = total cash returned ÷ market cap.
Net selling0P / 9S insiders · 1 funds hold · 0 Congress buys
Recent insidersANDERSON JOSEPH B JR · DirectorSELL$136,450
WALKER BRIAN C · DirectorSELL$136,450
BROWN LESLIE L · DirectorSELL$246,336
Schaum Richard O · DirectorSELL$112,247
Fund holders (13F)Ariel Investments (John W. Rogers Jr.)$182.3M2.0% of book
Bhealth · 77/100
Self-fundingSelf-funding — profitable · generates cash
- ●One-sided insider selling 9 insider sales and no open-market buys in the recent window.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.